Core Insights - Evotec SE's partner Bayer AG has initiated a Phase 2 clinical trial for SEMA3A mAb as a potential treatment for Alport syndrome [1] - A milestone payment to Evotec is expected upon the first dosing of the first study participant, anticipated in early 2026 [1] Company Overview - Evotec SE is involved in a multi-target research collaboration with Bayer AG focused on kidney diseases [1] - The collaboration agreement includes provisions for milestone payments based on clinical trial progress [1]